文献速递脊柱关节炎

银屑病关节炎患者报告结局测量工具的反应性与最小临床重要差异:一项前瞻性队列研究

Responsiveness and Minimum Clinically Important Difference in Patient-Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-04-26

该前瞻性队列研究纳入171例银屑病关节炎患者的266个治疗疗程,评估多种患者报告结局测量工具的反应性(标准化反应均值,SRM)和最小临床重要改善(MCII)。结果显示所有测量工具的SRM和MCII为小到中等,在基线疾病活动度较高的患者中更大;BASDAI总体SRM最佳,cDAPSA和PsAID12在高疾病活动度患者中最佳。

要点

  • 所有患者报告结局测量工具的SRM和MCII为小到中等,基线疾病活动度较高者更大。
  • BASDAI总体SRM最佳,在较低疾病活动度患者中也最佳。
  • cDAPSA和PsAID12在基线疾病活动度较高的患者中SRM最佳。

核心结论

  • 在真实世界人群中SRM和MCII相对较小,尤其在基线疾病活动度较低的患者中。
  • BASDAI、cDAPSA和PsAID12对变化有良好的敏感性,但试验中选择工具时应考虑入组患者的基线疾病活动度。

研究设计与样本

  • 在银屑病关节炎研究联盟内开展的前瞻性纵向队列研究。
  • 共纳入171例患者、266个治疗疗程;平均年龄51±13.8岁,女性占53%,基线平均肿胀关节数和压痛关节数分别为3和6。

主要发现

  • 所有测量工具的SRM和MCII为小到中等,但在基线疾病活动度较高的患者中更大。
  • BASDAI总体SRM最佳,在较低疾病活动度银屑病关节炎患者中也最佳。
  • cDAPSA和PsAID12在基线疾病活动度较高的患者中SRM最佳。

关键数值与推荐

  • MCII计算为报告最小改善的患者中评分变化的均值。
  • SRM和MCII在中等至高度活动性银屑病关节炎亚组与较低疾病活动度亚组之间进行比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the responsiveness to therapy and minimum clinically important improvement (MCII) for patient-reported outcome measures in psoriatic arthritis (PsA) and to examine the impact of baseline disease activity on the ability to demonstrate change. METHODS: A longitudinal cohort study was performed within the PsA Research Consortium. Patients completed several patient-reported outcomes, including the Routine Assessment of Patient Index Data, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Psoriatic Arthritis Impact of Disease 12-item (PsAID12) questionnaire, and others. The mean change in the scores between visits and standardized response means (SRMs) were calculated. The MCII was calculated as the mean change in score among patients who reported minimal improvement. SRMs and MCIIs were compared among subgroups with moderate to highly active PsA and those with lower disease activity. RESULTS: Among 171 patients, 266 therapy courses were included. The mean ± SD age was 51 ± 13.8 years, 53% were female, and the mean swollen and tender joint counts were 3 and 6, respectively, at baseline. SRMs and MCII for all measures were small to moderate, although greater among those with higher baseline disease activity. BASDAI had the best SRM overall and for less active PsA, and the clinical Disease Activity of PsA (cDAPSA) and PsAID12 were best for those with higher disease activity. CONCLUSION: SRMs and MCII were relatively small in this real-world population, particularly among those with lower disease activity at baseline. BASDAI, cDAPSA, and PsAID12 had good sensitivity to change, but selection for use in trials should consider the baseline disease activity of patients to be enrolled.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Karmacharya P, Stull C, Stephens-Shields A, et al. Responsiveness and Minimum Clinically Important Difference in Patient-Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2023. PMID: 36913210. doi:10.1002/acr.25111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。